evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,695 questions · 4,979 findings · 433 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 998 · 20%GRADE not reported 1,140 · 22.9%Very low 1,024 · 20.6%Low 1,029 · 20.7%Moderate 636 · 12.8%High 152 · 3.1%

Advanced haemodynamic monitoring vs protocol using standard measures such

All‐cause mortality Advanced haemodynamic monitoring · patients with proximal femoral fracture

It is very uncertain whether advanced haemodynamic monitoring changes all‐cause mortality Advanced haemodynamic monitoring compared with protocol using standard measures such (very low certainty).

1 finding from 1 review

Advanced haemodynamic monitoring vs protocol using standard measures such

Adverse outcomes ‐ all · patients with proximal femoral fracture

It is very uncertain whether advanced haemodynamic monitoring changes adverse outcomes ‐ all compared with protocol using standard measures such (very low certainty).

1 finding from 1 review

Herbal extracts (tea components; Chinese herbal mixture; freeze-dried black raspberry gel) vs placebo or no treatment

Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    3 months
    SoF 4, Histological changes (not improved) at 3 months: '2 studies (green tea extract capsules and freeze-dried raspberry gel) did not find evidence of benefit.' No GRADE. Effects text: Mallery raspberry RR 0.97…
    2 studies
    GRADE not reported

Surgical removal of the lesion (surgical excision, laser surgery, cryotherapy) vs Placebo or no treatment

Outcome not reported · People with a diagnosis of oral leukoplakia

The review found no eligible studies for this question.

1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    'We did not identify any RCTs that compared surgical treatments with placebo or no treatment.' Three surgical RCTs were found (Chee 2013, Lopez-Jornet 2013, Schwarz 2005) but all excluded because they did not include a…
    Studies not reported
    No studies found

Herbal extracts (tea components; Chinese herbal mixture; freeze-dried black raspberry gel) vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    up to 3 months
    SoF 4, Safety of the intervention up to 3 months: '3 studies measured adverse effects: green tea extract capsules caused high frequency (93%) of adverse effects of varying severity in 1 study; the mixed tea study did…
    3 studies
    GRADE not reported

Removal of predisposing habits (e.g. tobacco/alcohol cessation) vs Placebo or no treatment

Outcome not reported · People with a diagnosis of oral leukoplakia

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin A or retinoids (systemic or topical; incl. 13-cis-retinoic acid, acitretin) vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    4 to 12 months
    SoF 1, Safety of the intervention at 4 to 12 months: '3 studies (1 each evaluating topical acitretin, topical 13-cis-retinoic acid, 200,000 IU per week of vitamin A) found no adverse effects. Systemic 13-cis-retinoic…
    4 studies
    GRADE not reported

Bowman-Birk inhibitor vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    up to 6 months
    SoF 6, Safety of the intervention up to 6 months: 'Trial authors reported that there were no significant adverse effects. 33 participants in the intervention group reported 75 adverse effects. 25 participants in the…
    1 study
    GRADE not reported

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported.

9 findings from 1 review
Show 6 more findings

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

9 findings from 1 review
Show 6 more findings

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
10 findings from 1 review
Show 7 more findings

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether non-specific immunotherapy (recombinant interleukin-2 or BCG cell… changes disease-free survival compared with standard therapy alone (very low certainty).

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

2 findings from 1 review

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).

1 finding from 1 review